Mechanism of action
Etomidate is GABA receptor agonist that blocks neuroexcitation and induces unconsciousness.
Etomidate is imidazole-derived which is sedative-hypnotic that is a commonly used induction agent for RSI.
Dose
- The most common dose used is 0.3 mg/kg IV
- An adjusted body weight is recommended in morbidly obese patients.
Onset
- 15-45 seconds
Duration
- 3-12 minutes
Adverse effects
- Myoclonus can occur 25-63%
- Can be mistaken for seizure activity
- Pain on injection
- Thought to be due to diluent propylene glycol
- Adrenal Suppression
- Inhibits corticoneogenesis and 11β-hydroxylation which may decrease cortisol and aldosterone levels, resulting in prolonged suppression.
- Etomidate causes reduction in intraocular pressure (IOP).
Impact on Hemodynamics
Blood Pressure (BP) | Heart Rate (HR) | Cardiac Output (CO) | Intracranial Pressure (ICP) |
---|---|---|---|
↔ No Impact | ↔ No Impact | ↔ No Impact | ↓ Decrease |
Comment
- Etomidate has no analgesic effects.
Gold standard induction agent for RSI
Literature Review
Author, year | Design/ sample size | Intervention & Comparison | Outcome |
---|---|---|---|
Lyons, 2015 | Cohort study/ n=261 | Etomidate+ Succinylcholine (Group 1) vs Fentanyl+ ketamine+ rocuronium (Group 2) | Significantly better laryngeal views with fentanyl/ketamine/rocuronium group 100% first attempt intubation with fentanyl/ketamine/rocuronium group ↑ post-intubation MAP+ HR with etomidate + succinylcholine |
Bruder, 2015 | Cochrane Review | Etomidate Midazolam Propofol Ketamine | There was no difference in mortality, hospital LOS, duration of ventilation, and duration of vasopressors Etomidate associated with ↑ ACTH and ↓ in cortisol level |
Tekwani K, 2010 | RCT/ n=122 | Etomidate 0.3 mg/kg vs Midazolam 0.1 mg/kg | No significant differences in median hospital LOS (9.5 vs 7.3 days), ICU LOS (4.2 vs 3.1 days), In-hospital mortality ( 26% vs 43%), or ventilator days |
Jabre P, 2009 | RCT/ n=469 | Etomidate 0.3 mg/kg vs Ketamine 2 mg/kg | No difference in intubating condition, SOFA score, 28-day mortality, Ventilator free days, vasopressor support, or GCS |